ArticleCureus2026
Ketogenic Diet Versus Immunological Therapy in the Management of Refractory Epilepsy in Children.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn neuroclinical practice, refractory epilepsy can be identified only after the failure of several antiepileptic drugs (AEDs), so newer lines of treatment have been used, such as the ketogenic diet and rituximab.
methodsA total of 105 patients with refractory epilepsy were divided into three equal groups, each receiving a specific treatment: group R received rituximab, group K received a ketogenic diet, and group S received steroids for six months. Seizure frequency was recorded before and after enrollment.
resultsThe age to start AEDs, the age at enrollment in the study, and the duration of use of AEDs were comparable among the three groups. Family history was the highest in rituximab and consanguinity was the highest in steroid but without significant statistical difference with p value 0.829 and 0.941 respectively. There was a significant improvement (in the form of fit reduction) in all groups with a p-value of <0.001. This percentage of change was higher in rituximab (42.9%), followed by ketogenic diet (30%), then steroid (21%). The presence of a positive family history of epilepsy had a significant effect on improvement using any line of treatment, with a p-value of 0.022. Patients with a positive family history of epilepsy or positive consanguinity or multiple types of convulsions showed significant improvements with ketogenic drugs compared to other patients, with p-values of 0.012, 0.044, and <0.001, respectively.
conclusionAdding rituximab or a ketogenic diet to patients with refractory epilepsy provides better control of fits, with percentage improvements of 42.9% and 30%, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.